Plain-English translation of NCT04875819 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether two newer vaccine combinations—Menveo and Bexsero—can safely protect adults living with HIV from serious infections caused by meningococcus and pneumococcus bacteria. The study will compare how well these medications work compared to older vaccine options, and track how your immune system responds over five years.
People living with HIV are at higher risk for serious infections from meningococcus and pneumococcus bacteria, even when their HIV is well-controlled with treatment. This trial is designed to find the safest and most effective vaccination strategy to protect against these dangerous infections.
You likely qualify if…
You likely don't qualify if…
You will receive two vaccine injections—one at the start and another 60 days later—then a third vaccine dose at day 90. Throughout the study, you'll have blood drawn and throat swabs taken at several visits, with check-ins for at least five years to see how your immune system responded. You'll also report any side effects or health changes to the research team.
AI-generated summary from trial data · Jun 26, 2026 · Not medical advice
Denmark
Phase
Post-approval monitoring
Sponsor
Thomas Benfield
Enrollment target
~55 participants
Started
April 2021
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2021.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Michaela Tinggaard, M.D.
Department of Infectious Diseases, Hvidovre Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.